27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
This observational study provides further evidence that lipid-lowering agents are associated with decreased risk of dementia, whereas hyperlipidemia is associated with increased odds for non-Alzheimer-disease-type dementia. 5 key findings →
Participants: 9,294 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Emotion-oriented care is more effective with regard to the emotional adaptation in nursing homes of persons with a mild to moderate dementia. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Obesity in middle age increases the risk of future dementia independently of comorbid conditions. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Compared to people without diabetes, people with diabetes have a greater rate of decline in cognitive function and a greater risk of cognitive decline. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MCI was prevalent in 24.7% of participants at baseline. 2 key findings →
Design: prospective cohort Participants: 3,673 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The relation of blood pressure with cognitive function and dementia has, in recent years, received much attention from epidemiological research. 2 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Diabetes and current smoking were the strongest risk factors, but clusters including hypertension and heart disease also increased the risk of AD. 1 key finding →
Participants: 1,138 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This randomized, observer-blind, controlled trial examined the efficacy and safety of the traditional Chinese herbal medicine Yi-Gan San (YGS, Yokukan-San in Japanese) in the improvement of behavioral and psychological symptoms of dementia (BPSD) and activities of daily living (ADL). 4 key findings →
Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MCI as an entity is evolving and somewhat controversial. 1 key finding →
Participants: 93 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Linking the ADAMS dementia clinical assessment data to the wealth of available longitudinal HRS data on health, health care utilization, informal care, and economic resources and behavior, will provide a unique opportunity to study the onset of CIND and dementia in a nationally representative population-based sample, as well as the risk factors, prevalence, outcomes, and costs of CIND and dementia. 5 key findings →
Design: longitudinal study Participants: 856 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Those who viewed Caregiver's Friend: Dealing with Dementia 30 days postexposure demonstrated significant improvements in depression, anxiety, level and frequency of stress, caregiver strain, self-efficacy, and intention to seek help, as well as perceptions of positive aspects of caregiving. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Mini-Mental State Examination (MMSE) is recommended to test for cognitive impairment and to monitor medication response. 4 key findings →
Design: randomized controlled trial Participants: 7,073 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease. 4 key findings →
Participants: 156 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A larger WHR may be related to neurodegenerative, vascular, or metabolic processes that affect brain structures underlying cognitive decline and dementia. 3 key findings →
Design: cohort study Participants: 112 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. 3 key findings →
Design: cross-sectional Participants: 4,895 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This is a clinicopathologic study of a prospective, clinic-based cohort of patients with frontotemporal dementia (FTD)/Pick complex, who were followed to autopsy. 1 key finding →
Participants: 32 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Most prognostic studies on Parkinson disease have been hospital based or have applied register-based case-finding methods. 4 key findings →
Design: cohort study Participants: 6,969 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neurofibrillary tangles (NFTs) are the most common intraneuronal inclusion in the brains of patients with neurodegenerative diseases and have been implicated in mediating neuronal death and cognitive deficits.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although genomewide RNA expression analysis has become a routine tool in biomedical research, extracting biological insight from such information remains a major challenge.
Full summary, score breakdown and related studies → Original source Free full text
To explore neural correlates of cognitive decline in aging, we used longitudinal behavioral data to identify two groups of older adults (n = 40) that differed with regard to whether their performance on tests of episodic memory remained stable or declined over a decade. 4 key findings →
Design: longitudinal study Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer's disease. 2 key findings →
Design: cohort study Participants: 54 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nearly all persons had at least some AD pathology. 3 key findings →
Participants: 180 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Better knowledge of the preclinical phase of Alzheimer's disease would be an important advance to allow earlier treatment of this ominous disease. 2 key findings →
Participants: 1,050 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Formation of senile plaques composed of amyloid beta peptide, a pathological hallmark of Alzheimer disease, in human brains precedes disease onset by many years. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These data confirm the presence of cognitive impairment in 50% of patients with ALS and particularly implicate executive dysfunction and mild memory decline in the disease process. 4 key findings →
Participants: 279 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →